Share:
Original Article

Increased Prevalence of Bipolar Disorders in Hidradenitis Suppurativa: More Than a Striking Coexistence?

Author Affiliation(s)

Abstract

Introduction: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder of the hair follicle characterized by intense discharge and pain. Recently, HS's intrinsic association with neuropsychiatric disorders has become a focus of attention, and bipolar disorder (BD) emerged as a relevant topic for such an association.  


Objective: This study aimed to evaluate BD's prevalence among HS patients and present the HS and BD overlap patients' demographics, detailed clinical characteristics with a discussion on aggravating factors. 


Patients-Method: A retrospective chart review of 247 HS outpatients (Group-1) identified eight patients with BD. The frequency of BD in HS patients is compared to psoriasis patients (Group-2) and controls (Group-3) in age- and gender-matched groups. The demographic and clinical features of the 8 patients revealing HS-BD co-existence were analysed.   


Results: BD (n=9) was the 7th most common co-morbidity in the HS cohort. The frequency of BD is detected as 3.6% in group 1, 0.7% (n=1) in group 2, and 0.6% (n=1) in group 3, respectively.  Group 1 demonstrated an increased prevalence of BD compared to other groups (p=0.001). Of the 8 patients revealing HS and BD co-existence, 75% were active smokers, 62.5% were obese and 50% had metabolic syndrome.


Conclusion: This study's results reveal that the prevalence of BD in HS patients is higher than psoriasis patients and controls. The pathogenetic mechanisms underlying BD and HS co-existence needs to be investigated further. 

Keywords : hidradenitis suppurativa; bipolar disorders psychiatric; co-morbidity; co-existence

References

1. Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81(1):76-90. 2. Benhadou F, Villani AP, Guillem P. Hidradenitis Suppurativa and Bipolar Disorders: A Role for Lithium Therapy? Dermatology. 2020;236(4):305-6. 3. Tzur Bitan D, Berzin D, Cohen A. Hidradenitis Suppurativa and Bipolar Disorders: A Population-Based Study. Dermatology. 2020;236(4):298-304. 4. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016;387(10027):1561-72. 5. Ingram JR, Jenkins-Jones S, Knipe DW, Morgan CLI, Cannings-John R, Piguet V. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol. 2018;178(4):917-24. 6. Jemec GB, Kimball AB. Hidradenitis suppurativa: Epidemiology and scope of the problem. J Am Acad Dermatol. 2015;73(5 Suppl 1):S4-7. 7. Kelsoe JR. Arguments for the genetic basis of the bipolar spectrum. J Affect Disord. 2003;73(1-2):183-97. 8. Calkin CV, Gardner DM, Ransom T, Alda M. The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders. Ann Med. 2013;45(2):171-81. 9. Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, Miller DD, Haynes WG. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry. 2008;20(3):131-7. 10. Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry. 2011;23(1):40-7. 11. Zhao Z, Okusaga OO, Quevedo J, Soares JC, Teixeira AL. The potential association between obesity and bipolar disorder: A meta-analysis. J Affect Disord. 2016;202:120-3. 12. Huilaja L, Tiri H, Jokelainen J, Timonen M, Tasanen K. Patients with Hidradenitis Suppurativa Have a High Psychiatric Disease Burden: A Finnish Nationwide Registry Study. J Invest Dermatol. 2018;138(1):46-51. 13. Aithal V, Appaih P. Lithium induced hidradenitis suppurativa and acne conglobata. Indian J Dermatol Venereol Leprol. 2004;70(5):307-9. 14. Craddock N, Sklar P. Genetics of bipolar disorder. Lancet. 2013;381(9878):1654-62. 15. Jfri AH, O'Brien EA, Litvinov IV, Alavi A, Netchiporouk E. Hidradenitis Suppurativa: Comprehensive Review of Predisposing Genetic Mutations and Changes. J Cutan Med Surg. 2019;23(5):519-27. 16. Jalenques I, Ciortianu L, Pereira B, D'Incan M, Lauron S, Rondepierre F. The prevalence and odds of anxiety and depression in children and adults with hidradenitis suppurativa: Systematic review and meta-analysis. J Am Acad Dermatol. 2020;83(2):542-53. 17. Machado MO, Stergiopoulos V, Maes M, Kurdyak PA, Lin PY, Wang LJ, et al. Depression and Anxiety in Adults With Hidradenitis Suppurativa: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019;155(8):939-45. 18. Pavon Blanco A, Turner MA, Petrof G, Weinman J. To what extent do disease severity and illness perceptions explain depression, anxiety and quality of life in hidradenitis suppurativa? Br J Dermatol. 2019;180(2):338-45. 19. Akoglu G, Yildiz I, Karaismailoglu E, Esme P. Disease severity and poor mental health are the main predictors of stigmatization in patients with hidradenitis suppurativa. Dermatol Ther. 2021;34(3):e14910. 20. Zouboulis CC, Benhadou F, Byrd AS, Chandran NS, Giamarellos-Bourboulis EJ, Fabbrocini G, et al. What causes hidradenitis suppurativa ?-15 years after. Exp Dermatol. 2020;29(12):1154-70. 21. Anstey AV. gamma-Secretase gene mutations link acne inversa with Alzheimer's disease. Br J Dermatol. 2011;164(2):235-6. 22. Garg A, Strunk A. Risk of Alzheimer's disease is not increased among patients with hidradenitis suppurativa: A retrospective population-based cohort analysis. J Am Acad Dermatol. 2017;77(1):176-7. 23. Theut Riis P, Egeberg A, Gislason GH, Jemec GB. Patients with hidradenitis suppurativa have no increased risk of Alzheimer disease. Br J Dermatol. 2017;177(1):273-5. 24. Esme P, Esme M, Caliskan E. Increased prevalence of family history of Alzheimer's disease in hidradenitis suppurativa: Cross-sectional analysis of 192 HS patients. Dermatol Ther. 2020;33(6):e14219. 25. Horwitz T, Lam K, Chen Y, Xia Y, Liu C. A decade in psychiatric GWAS research. Mol Psychiatry. 2019;24(3):378-89. 26. Correa-Velloso JC, Goncalves MC, Naaldijk Y, Oliveira-Giacomelli A, Pillat MM, Ulrich H. Pathophysiology in the comorbidity of Bipolar Disorder and Alzheimer's Disease: pharmacological and stem cell approaches. Prog Neuropsychopharmacol Biol Psychiatry. 2018;80(Pt A):34-53. 27. Gültekin B, Kesebir S, Tamam LJPGY-CAiP. Bipolar disorder in Turkey. 2014;6(2):199-209. 28. Özdemir Ö, Doğan O. Sivas il merkezinde iki uçlu duygudurum bozukluğunun yaygınlığı, psikiyatrik eş tanıları ve hastaların yaşam kalitesi. 2014. 29. Cross-national comparisons of the prevalences and correlates of mental disorders. WHO International Consortium in Psychiatric Epidemiology. Bulletin of the World Health Organization. 2000;78(4):413-26. 30. Lee Y, Mansur RB, Brietzke E, Carmona NE, Subramaniapillai M, Pan Z, et al. Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression. Brain, behavior, and immunity. 2020. 31. McIntyre RS, Subramaniapillai M, Lee Y, Pan Z, Carmona NE, Shekotikhina M, et al. Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I/II depression: a randomized clinical trial. 2019;76(8):783-90. 32. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. 2013;70(1):31-41. 33. Mansur RB, Delgado-Peraza F, Subramaniapillai M, Lee Y, Iacobucci M, Rodrigues N, et al. Extracellular Vesicle Biomarkers Reveal Inhibition of Neuroinflammation by Infliximab in Association with Antidepressant Response in Adults with Bipolar Depression. Cells. 2020;9(4). 34. Soczynska JK, Kennedy SH, Goldstein BI, Lachowski A, Woldeyohannes HO, McIntyre RSJN. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? 2009;30(4):497-521.

Send mail to Author


Send Cancel